By Chris Wack
4D Molecular Therapeutics shares were up 33% to $23.20 in premarket trading after the company said it saw positive interim data from a Phase 2 clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration patients.
The company said results from the Phase 1 and interim results from Phase 2 cohorts of the study confirm that 4D-150 is well tolerated and maintains stable visual acuity in previously treated high-need patients.
4D-150 also showed that it significantly reduces treatment burden while effectively controlling disease activity without fluid fluctuations.
4D Molecular is set to begin Phase 3 trials.
Write to Chris Wack at [email protected]
Read the full article here
